quinazolines has been researched along with simvastatin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Dugi, KA; Graefe-Mody, U; Huettner, S; Ring, A; Stähle, H | 1 |
| Han, JY; Hyung, LS; Kim, HT; Lee, JS; Lee, SH; Moon, YJ; Yoo, NJ; Yun, T | 1 |
| Hwang, KE; Jeong, ET; Kim, BR; Kim, HR; Kim, YS; Kwon, SJ; Park, DS; Yoon, KH | 1 |
| Kang, HH; Kim, IK; Lee, HI; Lee, HY; Lee, SH; Mo, JY; Moon, HS; Yeo, CD | 1 |
| Go, YJ; Han, JY; Joo, J; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Lim, KY | 1 |
| Abbas, A; Basak, S; Bhattacharya, P; Deep Punetha, V; Dey, S; Gopal Sahoo, N; Mondal, S; Saha, A | 1 |
| Bi, F; Bi, NX; Gong, QY; Liu, BS; Liu, Q; Nie, YZ; Tang, QL; Xia, HW; Zhou, JT; Zhou, S | 1 |
3 trial(s) available for quinazolines and simvastatin
| Article | Year |
|---|---|
Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.
Topics: Adult; Area Under Curve; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Simvastatin | 2010 |
A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Simvastatin; Treatment Outcome | 2011 |
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Simvastatin; Survival Analysis; Treatment Outcome | 2017 |
5 other study(ies) available for quinazolines and simvastatin
| Article | Year |
|---|---|
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catenins; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Simvastatin; Survivin | 2014 |
The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Quinazolines; Simvastatin; Up-Regulation | 2016 |
Fabrication of β-cyclodextrin-mediated single bimolecular inclusion complex: characterization, molecular docking, in-vitro release and bioavailability studies for gefitinib and simvastatin conjugate.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; beta-Cyclodextrins; Biological Availability; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gefitinib; Male; Mice; Molecular Docking Simulation; Quinazolines; Rats, Wistar; Simvastatin; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2017 |
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphoproteins; Polyisoprenyl Phosphates; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Simvastatin; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |